Kaitu’u-Lino, Tu’uhevaha J.
MacDonald, Teresa M. http://orcid.org/0000-0001-9099-7745
Cannon, Ping
Nguyen, Tuong-Vi
Hiscock, Richard J.
Haan, Nick http://orcid.org/0000-0001-8898-0434
Myers, Jenny E. http://orcid.org/0000-0003-0913-2096
Hastie, Roxanne
Dane, Kirsten M.
Middleton, Anna L.
Bittar, Intissar
Sferruzzi-Perri, Amanda N. http://orcid.org/0000-0002-4931-4233
Pritchard, Natasha
Harper, Alesia
Hannan, Natalie J.
Kyritsis, Valerie
Crinis, Nick
Hui, Lisa
Walker, Susan P.
Tong, Stephen
Funding for this research was provided by:
RANZCOG Research Foundation
The Stillbirth Foundation
Tommy's
National Institute Health Research Manchester Academic Health Science Centre
RCUK | Biotechnology and Biological Sciences Research Council
Centre for Trophoblast Research
Department of Health | National Health and Medical Research Council (1105603, 1065854, 1136418, 1183854)
Article History
Received: 27 July 2019
Accepted: 24 April 2020
First Online: 15 May 2020
Competing interests
: T.K.L., T.M.M., S.P.W., and S.T. hold a provisional patent (PCT/AU2019/050516) relating to the use of SPINT1 and syndecan as diagnostic markers in pregnancy. N.H. is the owner of Foresight Health, which has a research and commercialization agreement with The University of Melbourne relating to the development of diagnostic markers of placental insufficiency, and rights to the patent (PCT/AU2019/050516). The remaining authors have no competing interests to declare.